Fig. 6: PD1 and TIGIT engagement synergistically inhibit DOT cell function.
a, Expression of NKG2D, DNAM1 or TIM3 in PD1−TIGIT− and PD1+TIGIT+ DOT cells in tumors from xenografted mice (n = 5 mice). b, Expression of CD107a, granzyme B, IFNγ and TNF in PD1−TIGIT− and PD1+TIGIT+ DOT cells in tumors after 3 h of PMA and ionomycin stimulation (n = 6 mice). In a and b, data points from the same mice are connected by lines and were analyzed by a two-tailed paired t-test. The experiment was performed three times, with similar results. c, PDL1 expression on SW620 cells upon 24-h incubation with either rIFNγ DOT cells or DOT cells and neutralizing anti-IFNγ antibody, measured by flow cytometry (the means of the technical replicates of n = 2 independent experiments are presented). Data are presented as the means ± s.e.m. and were analyzed by a one-way ANOVA with Tukey’s post hoc test. d, Geometric mean fluorescence intensity of PVR levels in PDL1− and PDL1+ SW620 cells upon IFNγ or DOT cell exposure (the means of the technical replicates of n = 2 independent experiments are presented), measured by flow cytometry and analyzed by a two-tailed paired t-test. e, Percentage of DOT cells expressing granzyme B and perforin after 24-h incubation with plate-bound PVR and/or PDL1 in the presence or not of anti-DNAM1 and anti-CD96 blocking antibodies (the means of the technical replicates of n = 2 independent experiments are presented).
